136 related articles for article (PubMed ID: 19115689)
1. Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients.
Chod J; Zavadova E; Halaska MJ; Strnad P; Fucikova T; Rob L
Eur J Gynaecol Oncol; 2008; 29(6):613-6. PubMed ID: 19115689
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.
Kong FM; Anscher MS; Murase T; Abbott BD; Iglehart JD; Jirtle RL
Ann Surg; 1995 Aug; 222(2):155-62. PubMed ID: 7543740
[TBL] [Abstract][Full Text] [Related]
3. [Transforming growth factor-beta 1 as a marker in patients with operable breast cancer].
Chod J; Závadová E; Halaska M; Strnad P; Rob L; Fucíková T
Ceska Gynekol; 2007 Apr; 72(2):112-5. PubMed ID: 17639732
[TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
5. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status.
Blackwell K; Haroon Z; Broadwater G; Berry D; Harris L; Iglehart JD; Dewhirst M; Greenberg C
J Clin Oncol; 2000 Feb; 18(3):600-8. PubMed ID: 10653875
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-α and TGF-β1.
Tripsianis G; Papadopoulou E; Romanidis K; Katotomichelakis M; Anagnostopoulos K; Kontomanolis E; Botaitis S; Tentes I; Kortsaris A
Asian Pac J Cancer Prev; 2013; 14(11):6813-20. PubMed ID: 24377611
[TBL] [Abstract][Full Text] [Related]
7. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
8. The sentinel lymph node biopsy in breast cancer.
Weerts JM; Maweja S; Tamigneaux I; Dallemagne B; Jourdan JL; Markiewicz S; Monami B; Wahlen Ch; Lastra M; Hénon V; Gomez P; Lilet H; Dwelshauwers J; Graas MP; Focan Ch; Lipczei B; Abraham F; Jehaes C
Acta Chir Belg; 2002 Apr; 102(2):110-3. PubMed ID: 12051082
[TBL] [Abstract][Full Text] [Related]
9. Stage-related plasma values of transforming growth factor-beta1 are steroid receptors dependent.
Todorović-Raković N; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Clin Exp Med; 2009 Dec; 9(4):313-7. PubMed ID: 19458909
[TBL] [Abstract][Full Text] [Related]
10. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of sentinel lymph node biopsy in axillary lymph nodes at the early stages of breast cancer.
Pusina S
Med Arch; 2013; 67(4):252-5. PubMed ID: 24520746
[TBL] [Abstract][Full Text] [Related]
12. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
13. Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Roumen RM; Siesling S; van der Heiden-van der Loo M; Lobbezoo DJ; Tjan-Heijnen VC; Voogd AC
Clin Breast Cancer; 2016 Aug; 16(4):e75-82. PubMed ID: 27116948
[TBL] [Abstract][Full Text] [Related]
14. The predicted probability of having positive non-sentinel lymph nodes in patients who received neoadjuvant chemotherapy for large operable breast cancer.
Evrensel T; Johnson R; Ahrendt G; Bonaventura M; Falk JS; Keenan D; Soran A
Int J Clin Pract; 2008 Sep; 62(9):1379-82. PubMed ID: 17309608
[TBL] [Abstract][Full Text] [Related]
15. Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.
Reynders A; Brouckaert O; Smeets A; Laenen A; Yoshihara E; Persyn F; Floris G; Leunen K; Amant F; Soens J; Van Ongeval C; Moerman P; Vergote I; Christiaens MR; Staelens G; Van Eygen K; Vanneste A; Van Dam P; Colpaert C; Neven P
Breast; 2014 Aug; 23(4):453-9. PubMed ID: 24768478
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
17. Sentinel node biopsy in elderly breast cancer patients.
Gennari R; Rotmensz N; Perego E; dos Santos G; Veronesi U
Surg Oncol; 2004 Dec; 13(4):193-6. PubMed ID: 15615656
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of transforming growth factor beta1 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Sheen CW; Eng HL; Chen WJ
Arch Surg; 2001 Aug; 136(8):937-40. PubMed ID: 11485532
[TBL] [Abstract][Full Text] [Related]
19. Axillary ultrasound and Fine-Needle Aspiration Cytology in the preoperative staging of axillary node metastasis in breast cancer patients.
Gipponi M; Fregatti P; Garlaschi A; Murelli F; Margarino C; Depaoli F; Baccini P; Gallo M; Friedman D
Breast; 2016 Dec; 30():146-150. PubMed ID: 27728855
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer.
Choi SH; Barsky SH; Chang HR
Breast J; 2003; 9(3):153-62. PubMed ID: 12752622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
